Last reviewed · How we verify

NCT04793867

Regional Phenotyping of CF and Non-CF Bronchiectasis

Recruiting now Last updated 20 February 2025
What this trial tests

trial testing Xenon in Cystic Fibrosis in 100 participants. Currently enrolling.

Timeline
8 February 2021
Primary endpoint
31 March 2026
31 March 2027

Quick facts

Lead sponsorChildren's Hospital Medical Center, Cincinnati
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date8 February 2021
Primary completion31 March 2026
Estimated completion31 March 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital Medical Center, Cincinnati

Who can join

Adults 5 to 100, any sex, with Cystic Fibrosis or Non-CF Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Xenon

Trials testing the same drug.

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

Other Children's Hospital Medical Center, Cincinnati trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04793867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing